Ebola virus' deadly effect explained. By DAMARAIS CHRISTENSEN, UPI Science News. WASHINGTON, July 31 -- The words "Ebola virus" brings a shiver to people who read thrillers or real-life stories ...

More than four years after the Ebola epidemic in West Africa, scientists are still uncovering sobering new information about the lasting effects of the virus on survivors. A study published Monday ...

New research suggests that the massive and destructive inflammation that characterizes Ebola virus disease may be caused by the release of foreign proteins from infected cells.

Ebola's physical legacy doesn't end when a patient leaves the hospital. A follow-up of the small group of patients treated in the U.S. finds many experienced various symptoms for months.

W A S H I N G T O N, July 31 -- A protein that disrupts blood vesselwalls explains why victims of the Ebola virus suffer fromghastly and often deadly bleeding, and could offer a target fora ...

According to the World Health Organization (WHO) the Ebola virus is killing 70% of the people who contract the disease. The WHO believes there could be up to 10,000 new Ebola cases per week alone ...

Post-Ebola syndrome continues to affect some of the approximately 17,000 people who survived the virus as many have eye, musculoskeletal or neurological symptoms, researchers have found in recent ...

People who survive Ebola may suffer "severe" neurological and psychiatric problems long after they recover from the virus, according to a new study published Wednesday.. Some cases of so-called ...

Over the years the Ebola virus has wiped out a significant number of great apes, threatening to reduce those populations to vulnerable levels. In Louisiana, a controversial effort is underway to ...

As concern grows about Ebola, there’s ample precedent. Deutsche Bank’s Andrew Zarnett examined the 2003 outbreak of the Severe Acute Respiratory Syndrome for clues.

Side effects temporarily halted Ebola vaccine safety trial Dr. Claire-Anne Siegrist, head of the Center of Vaccinology of the Geneva University Hospital, talks about the VSV-ZEBOV vaccine trial on ...